In aseptic manufacturing, product loss is inevitable. But when you’re working with high-value or small-batch therapies, every lost milliliter means fewer doses and higher per-unit costs that can stifle a clinical trial or cause issues with drug supply.
This whitepaper breaks down where product loss occurs throughout formulation, filtration, filling, and testing. We then offer practical strategies and highlight specialized equipment to optimize yield
What You’ll Learn
- A stage-by-stage breakdown of where and why product is lost
- How much can be saved, with a side-by-side comparison of baseline vs. optimized process yield
- Steps a CDMO can take to maximize yield
- A real-world case study from Argonaut Manufacturing Services achieving 99% theoretical yield in a 500-vial fill
Who Should Read This
This whitepaper was written for sponsors working with limited or high-value drug substance, teams preparing for clinical or commercial fill-finish, and anyone evaluating CDMOs on true yield performance.